Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 2
2015 7
2016 5
2017 9
2018 23
2019 21
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, Chen E, Gau CL, Palmaer E, Shoaepour K, Shah D, Speare V, Gandomi S, Chao E. LaDuca H, et al. Genet Med. 2014 Nov;16(11):830-7. doi: 10.1038/gim.2014.40. Epub 2014 Apr 24. Genet Med. 2014. PMID: 24763289 Free PMC article.
PURPOSE: The aim of this study was to determine the clinical and molecular characteristics of 2,079 patients who underwent hereditary cancer multigene panel testing. METHODS: Panels included comprehensive analysis of 14-22 cancer susceptibility genes ( …
PURPOSE: The aim of this study was to determine the clinical and molecular characteristics of 2,079 patients who underwent hereditary
Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics.
Hamilton JG, Robson ME. Hamilton JG, et al. Hastings Cent Rep. 2019 May;49 Suppl 1(Suppl 1):S44-S52. doi: 10.1002/hast.1016. Hastings Cent Rep. 2019. PMID: 31268573 Free PMC article.
In recent years, with both the development of next-generation sequencing approaches and the Supreme Court decision invalidating gene patents, declining costs have contributed to the emergence of a new model of hereditary cancer genetic testing. Multigene panel
In recent years, with both the development of next-generation sequencing approaches and the Supreme Court decision invalidating gene patents …
An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Piccinin C, Panchal S, Watkins N, Kim RH. Piccinin C, et al. Expert Rev Anticancer Ther. 2019 Sep;19(9):787-801. doi: 10.1080/14737140.2019.1659730. Epub 2019 Sep 7. Expert Rev Anticancer Ther. 2019. PMID: 31469018 Review.
A variety of genes have been included on these panels without certainty of their clinical utility. Pertinent current and historical literature was reviewed to provide an up-to-date snapshot of the changing landscape of the use of gene panel tests in the conte …
A variety of genes have been included on these panels without certainty of their clinical utility. Pertinent current and histo …
Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS, Lee ST, Nam EJ, Han JW, Lee JY, Kim J, Kim TI, Park HS. Park JS, et al. BMC Cancer. 2018 Jan 16;18(1):83. doi: 10.1186/s12885-017-3940-y. BMC Cancer. 2018. PMID: 29338689 Free PMC article.
BACKGROUND: We evaluated the incidence and spectrum of pathogenic and likely pathogenic variants of cancer susceptibility genes in BRCA1/2 mutation-negative Korean patients with a high risk for hereditary breast cancer using a comprehensive multigene panel th …
BACKGROUND: We evaluated the incidence and spectrum of pathogenic and likely pathogenic variants of cancer susceptibility genes in BRCA1/2 m …
A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
de Souza Timoteo AR, Gonçalves AÉMM, Sales LAP, Albuquerque BM, de Souza JES, de Moura PCP, de Aquino MAA, Agnez-Lima LF, Lajus TBP. de Souza Timoteo AR, et al. Breast Cancer Res Treat. 2018 Dec;172(3):637-646. doi: 10.1007/s10549-018-4938-0. Epub 2018 Aug 29. Breast Cancer Res Treat. 2018. PMID: 30159786
Herein we aimed to determine the clinical and molecular characteristics of Brazilian patients who underwent oncogenetic counseling and genetic testing of a panel of high-risk and moderate-risk genes from 2009 to 2017. METHODS: Massively parallel sequencing was applied in 1 …
Herein we aimed to determine the clinical and molecular characteristics of Brazilian patients who underwent oncogenetic counseling and genet …
Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA, Susswein LR, Marshall ML, Roberts ME, Mester JL, Speyer D, Williams RNW, Knapke SC, Solomon SR, Murphy PD, Klein RT, Hruska KS, Solomon BD. Theobald KA, et al. Ann Surg Oncol. 2018 Nov;25(12):3556-3562. doi: 10.1245/s10434-018-6581-8. Epub 2018 Aug 30. Ann Surg Oncol. 2018. PMID: 30167906
BACKGROUND: Knowledge of a germline pathogenic/likely pathogenic variant (PV) may inform breast cancer management. BRCA1/2 PV often impact surgical decisions, but data for multi-gene panel testing are lacking. Expedited genetic testing reduces turn-around times base …
BACKGROUND: Knowledge of a germline pathogenic/likely pathogenic variant (PV) may inform breast cancer management. BRCA1/2 PV often impact s …
Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
Ow SGW, Ong PY, Lee SC. Ow SGW, et al. PLoS One. 2019 Mar 15;14(3):e0213746. doi: 10.1371/journal.pone.0213746. eCollection 2019. PLoS One. 2019. PMID: 30875412 Free PMC article.
Testing beyond BRCA1/2 impacted management for 15.9% (22/138) of carriers, but extensive testing identified variants of uncertain significance (VUS) in up to 44.5% of probands. Restricting multigene panel testing to a guideline-based 20-gene panel including L …
Testing beyond BRCA1/2 impacted management for 15.9% (22/138) of carriers, but extensive testing identified variants of uncertain significan …
Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J, Seng S, Yoo J, Equivel P, Lum SS. Chang J, et al. Ann Surg Oncol. 2019 Oct;26(10):3389-3396. doi: 10.1245/s10434-019-07595-2. Epub 2019 Jul 24. Ann Surg Oncol. 2019. PMID: 31342386 Clinical Trial.
BACKGROUND: Rising use of multigene panel testing has led to increased identification of variants of uncertain significance (VUS). ...There were no differences in the use of post-test imaging, oophorectomy, or colonoscopy based on variant findings or age. CONCLUSION …
BACKGROUND: Rising use of multigene panel testing has led to increased identification of variants of uncertain significance (V …
Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer.
Moslim MA, Heald B, Tu C, Burke CA, Walsh RM. Moslim MA, et al. Surgery. 2018 Oct;164(4):754-759. doi: 10.1016/j.surg.2018.05.059. Epub 2018 Aug 23. Surgery. 2018. PMID: 30145018
The implications of CDH1 mutations detected with multigene panels in those without family history of HDGC are uncertain. ...The most common indication for CDH1 genetic screening was family history of hereditary diffuse gastric cancer (known risk) in 10 patien …
The implications of CDH1 mutations detected with multigene panels in those without family history of HDGC are uncertain. ...Th …
Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing.
Lorans M, Dow E, Macrae FA, Winship IM, Buchanan DD. Lorans M, et al. Clin Colorectal Cancer. 2018 Jun;17(2):e293-e305. doi: 10.1016/j.clcc.2018.01.001. Epub 2018 Jan 11. Clin Colorectal Cancer. 2018. PMID: 29454559 Free article. Review.
The practice of clinical genetics is currently transitioning from phenotype-directed single gene testing to multigene panels, now offered by numerous providers. For CRC, the genes included across these panels vary, ranging from well established, clinically ac …
The practice of clinical genetics is currently transitioning from phenotype-directed single gene testing to multigene panels, …
69 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback